OTCMKTS:MNKKQ Mallinckrodt (MNKKQ) Stock Price, News & Analysis $0.02 0.00 (0.00%) As of 07/18/2022 Add Compare Share Share Stock Analysis Stock Analysis About Mallinckrodt Stock (OTCMKTS:MNKKQ) Get Mallinckrodt alerts:Sign Up Key Stats Today's Range$0.02▼$0.0250-Day Range$0.02▼$0.0252-Week Range$0.00▼$0.59VolumeN/AAverage Volume548,094 shsMarket Capitalization$1.70 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Mallinckrodt plc is a specialty pharmaceutical company that develops, manufactures and markets specialty branded and generic medicines. Its portfolio has historically focused on autoimmune and rare diseases, neurology, pain management, critical care and other complex therapeutic areas. The company serves hospitals, specialty physicians, pharmacies and patients primarily in the United States, with operations and commercial activities in selected international markets. Mallinckrodt’s principal products have included Acthar Gel, a repository corticotropin injection used for certain inflammatory and autoimmune conditions; INOmax, an inhaled nitric oxide therapy used in neonatal critical care; and Therakos photopheresis systems and related products used in extracorporeal photopheresis. The company has also marketed specialty generic and hospital medicines, including treatments for pain, inflammation and critical-care applications. Founded in the 19th century, Mallinckrodt operated for many years as part of larger pharmaceutical businesses before becoming an independent public company in 2013 following its separation from Covidien. The company subsequently underwent significant financial and operational restructuring, including Chapter 11 bankruptcy proceedings, and emerged from its latest restructuring in 2024. Mallinckrodt’s business continues to be centered on specialty therapies and medically complex products.AI Generated. May Contain Errors. Read More Receive MNKKQ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mallinckrodt and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MNKKQ Stock News HeadlinesMallinckrodt plc (MNKTQ) Q3 2025 Earnings Call TranscriptNovember 10, 2025 | seekingalpha.comMallinckrodt to file for chapter 11 bankruptcy again and leave $1 ...August 24, 2025 | marketwatch.com"How Much Can I Actually Spend Each Year With $2.5M Saved?"Having $2.5 million saved puts you ahead of most Americans, but how long it lasts depends on the decisions you make with it. Using the 4% rule as a benchmark, that balance could translate to about $100,000 in year one, adjusted upward for inflation each year after. But the 4% rule has potential downsides and may not fit every portfolio. A financial advisor can help size and structure a retirement budget around your income sources, taxes, and goals. SmartAsset's free quiz matches nearly 50,000 people each month with vetted fiduciary advisors.September 26 at 1:00 AM | SmartAsset (Ad)S&P Global raises Endo ratings on Mallinckrodt merger completionAugust 1, 2025 | investing.comMallinckrodt, Endo Complete Merger to Create Global, Scaled, Diversified Therapeutics LeaderAugust 1, 2025 | prnewswire.comMallinckrodt Receives Necessary Ruling from Irish High Court to Combine with Endo, Inc.July 17, 2025 | prnewswire.comMallinckrodt and Endo Shareholders Approve Combination to Create a Global, Scaled, Diversified Pharmaceuticals LeaderJune 13, 2025 | prnewswire.comMallinckrodt, Endo Announce Planned Leadership Team for Merged CompanyJune 9, 2025 | prnewswire.comSee More Headlines MNKKQ Stock Analysis - Frequently Asked Questions How have MNKKQ shares performed this year? Mallinckrodt's stock was trading at $0.02 at the beginning of 2026. Since then, MNKKQ shares have increased by 0.0% and is now trading at $0.02. How do I buy shares of Mallinckrodt? Shares of MNKKQ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today9/25/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolOTCMKTS:MNKKQ CIK1567892 Webwww.mallinckrodt.com Phone(531) 696-0000FaxN/AEmployees2,800Year Founded1867Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$911.20 million Net Margins-56.33% Pretax Margin-87.42% Return on Equity-59.80% Return on Assets-16.98% Debt Debt-to-Equity Ratio2.23 Current Ratio2.73 Quick Ratio1.44 Sales & Book Value Annual Sales$1.91 billion Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$19.03 per share Price / Book0.00Miscellaneous Outstanding Shares84,780,000Free Float81,756,000Market Cap$1.70 million OptionableNot Optionable BetaN/A Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (OTCMKTS:MNKKQ) was last updated on 9/26/2026 by MarketBeat.com Staff. From Our PartnersA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredShocking new footage just releasedGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | Sponsored"How Much Can I Actually Spend Each Year With $2.5M Saved?"Having $2.5 million saved puts you ahead of most Americans, but how long it lasts depends on the decisions you...SmartAsset | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredThe retirement stock I'd buy before Nvidia todayIn 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...Chaikin Analytics | SponsoredAnalyst nicknamed “The Prophet” issues new warning for AmericaWhitney Tilson exposed a major company on 60 Minutes in an Emmy-winning investigation - the stock lost nearly ...Stansberry Research | SponsoredThis free guide explains options the way they should be taughtMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...Base Camp Trading | SponsoredBuffett's Final Warning: "The Dollar Is Going to Hell"On May 3rd, 2025, Warren Buffett looked at his shareholders for the last time and said: "The dollar is going t...Decentralized Masters | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mallinckrodt plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Mallinckrodt With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
